Table 1:
Study population characteristics, overall n = 304
| Tac/MTX (N=147) | PTCy (N=157) | p-value | |
|---|---|---|---|
| Sex, n (%) | 0.488a | ||
| Female | 65 (44.2%) | 63 (40.1%) | |
| Male | 82 (55.8%) | 94 (59.9%) | |
| Age | 0.634b | ||
| Mean (standard deviation) | 64.8 (7.9) | 64.4 (8.33) | |
| Median (Range) | 66.3 (26.3 – 75.6) | 66 (22.1 – 78.6) | |
| Ethnicity, n (%) | 0.067a | ||
| Hispanic or Latino | 15 (10.2%) | 7 (4.5%) | |
| Not Hispanic or Latino | 131 (89.1%) | 149 (94.9%) | |
| Not Reported | 0 (0.0%) | 1 (0.6%) | |
| Unknown | 1 (0.7%) | 0 (0.0%) | |
| Race, n (%) | 0.325a | ||
| American Indian or Alaskan Native | 1 (0.7%) | 0 (0.0%) | |
| Asian | 3 (2.0%) | 8 (5.1%) | |
| Black | 3 (2.0%) | 7 (4.5%) | |
| White | 131 (89.1%) | 133 (84.7%) | |
| Unknown | 9 (6.1%) | 9 (5.7%) | |
| Primary Disease, n (%) | 0.686a | ||
| Acute lymphoblastic leukemia (ALL) | 17 (11.6%) | 9 (5.7%) | |
| Acute myelogenous leukemia (AML) | 72 (49.0%) | 80 (51.0%) | |
| Chronic myelogenous leukemia (CML) | 4 (2.7%) | 4 (2.6%) | |
| Chronic lymphocytic leukemia (CLL) | 2 (1.4%) | 1 (0.6%) | |
| Myelodysplastic syndrome (MDS) | 41 (27.9%) | 50 (31.8%) | |
| Hodgkin lymphoma | 1 (0.7%) | 1 (0.6%) | |
| Indolent non-Hodgkin lymphoma (NHL) | 0 (0.0%) | 2 (1.3%) | |
| T-cell NHL | 5 (3.4%) | 6 (3.8%) | |
| Aggressive NHL | 4 (2.7%) | 4 (2.6%) | |
| Karnofsky Performance Score, n (%) | 0.422a | ||
| At Least 90 | 73 (49.7%) | 86 (54.8%) | |
| Less than 90 | 74 (50.3%) | 71 (45.2%) | |
| Disease Risk Index, n (%) | 0.567a | ||
| Low | 15 (10.2%) | 12 (7.6%) | |
| Intermediate | 85 (57.8%) | 99 (63.1%) | |
| High or Very High | 47 (32.0%) | 46 (29.3%) | |
| Donor Type and HLA Matching, n (%) | 0.539a | ||
| Related Donor 6/6 | 46 (31.3%) | 40 (25.5%) | |
| Unrelated Donor 8/8 | 96 (65.3%) | 112 (71.3%) | |
| Unrelated Donor 7/8 | 5 (3.4%) | 5 (3.2%) | |
| Donor/Recipient CMV Status, n (%) | 0.012a | ||
| Positive/Positive | 49 (33.3%) | 48 (30.6%) | |
| Positive/Negative | 23 (15.6%) | 14 (8.9%) | |
| Negative/Positive | 27 (18.4%) | 53 (33.8%) | |
| Negative/Negative | 48 (32.7%) | 41 (26.1%) | |
| Received Conditioning Regimen, n (%) | 0.071a | ||
| Fludarabine/Bulsulfan | 51 (34.7%) | 41 (26.1%) | |
| Fludarabine/Melphalan | 82 (55.8%) | 91 (58.0%) | |
| Fludarabine/Cyclophosphamide | 0 (0.0%) | 5 (3.2%) | |
| Fludarabine/TBI | 0 (0.0%) | 1 (0.6%) | |
| Fludarabine/TBI/Cyclophosphamide | 14 (9.5%) | 19 (12.1%) |
a:
Fisher’s exact test
b:
Wilcoxon Rank Sum Test, TBI: total body irradiation, HLA: human leukocyte antigen, CMV: Cytomegalovirus.